Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. Issue 12 (11th November 2022)

• Record Type: Journal Article
• Authors: Chen, Junyu; Cao, Dongyan; Yang, Jiaxin; Yu, Mei; Zhou, Huimei; Cheng, Ninghai; Wang, Jinhui; Zhang, Ying; Peng, Peng; Shen, Keng
• Is Part Of: International journal of gynecological cancer. Volume 32:Issue 12(2022)
• Page Start: 1561
• Page End: 1567
• Publication Date: 2022-11-11
• Subjects: Carcinoma -- Gynecology -- Uterine Cancer -- Endometrial Hyperplasia; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-003882
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility. Methods: Patients at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital between January 2013 and December 2020 were retrospectively reviewed. A total of 179 patients who were unsuitable to undergo treatment with high-dose oral progestin, including those with progestin allergies, body mass index ≥30 kg/m 2, liver and/or renal dysfunction, hypercoagulable state, and thrombosis were included. Patient data were retrieved from medical records and a prospectively maintained database that represented the standard protocol was followed for all patients. Clinical characteristics, treatment outcomes, adverse events, and reproductive outcomes were collected and analyzed. Logistic regression models were constructed to determine the associations between complete remission, recurrence, and fertility. Results: Overall, 169 patients (94.4%) achieved complete remission; 58 (96.7%) had atypical endometrial hyperplasia and 111 (93.3%) had endometrial carcinoma. The complete remission rates for the GnRHa plus LNG-IUD and GnRHa plus letrozole groups were 93.5% and 95.8%, respectively. The median time to complete remission was 6 (range 3–18) months: 4 (range 3–10) months for atypical endometrial hyperplasia and 8 (range 3–18) months for endometrial carcinoma. After a median follow-up of 27.5 (range 3–92) months, 41 (24.3%) women developed recurrence, with a median recurrence time of 17 (range 6–77) months. Of the patients with complete remission, 134 patients desired to conceive and 42 (32.3%) became pregnant, 24 (17.9%) were successfully delivered, 5 (3.7%) were still pregnant, while 13 miscarried. Conclusion: GnRHa combined treatment provides favorable oncological and reproductive outcomes. Larger multi-institutional studies are required to confirm these preliminary findings.